Bristol-Myers Slips Suit Over $6.4B Investor Payment, For Now

By Lauren Berg · March 1, 2023, 10:43 PM EST

A Manhattan federal judge Wednesday dismissed a proposed class action alleging Bristol-Myers Squibb Co. and its executives intentionally delayed the U.S. Food and Drug Administration's approval of a cancer treatment developed...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

SM Merger/Arbitrage, L.P. et al v. Bristol-Myers Squibb Company et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

October 06, 2021

Recent Articles By Lauren

November 20, 2024
Musk, Ramaswamy Say High Court Rulings OK Federal Cuts
November 15, 2024
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
November 12, 2024
J&J Says HHS Is Thwarting Transparency Of Drug Discounts
October 30, 2024
FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
October 18, 2024
Oklahoma Brings Title X Funding Cut Fight To Justices
October 11, 2024
Feds Target Ill. Hospital CEO As $19M Theft Probe Widens
October 11, 2024
Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases
September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 30, 2024
Bristol-Myers Beats Celgene Investors' Drug Delay Suit
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule